CNSP News and Press, CNS Pharmaceuticals Inc. From 01/23/23

The American Cancer Society Journals estimates that there will be 1.9 million additional cancer diagnoses and 609,820 million cancer deaths this year. The deadly disease affects tens of millions of people globally and... Read more » NOTE TO INVESTORS:  The latest news and upd...

Researchers at Brigham and Women’s Hospital may have found another way to treat cancer; the new approach involves transforming cancer cells into anti-cancer agents. The researchers developed the new therapy approach, which can train the immune system to prevent the disease from recurring...

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced an investigator-initiated phase 1b /2 trial evaluating the company’s novel anthra...

CNS Pharmaceuticals Announces Investigator-Initiated Phase 1b/2 Trial to be Conducted at the Pomeranian Medical University in Poland PR Newswire Study to evaluate Berubicin for the treatment of newly diagnosed and relapsed/refractory primary central nervous system lymphoma (PC...

- Live video webcast presentations with participating companies - FRENCHTOWN, NJ / ACCESSWIRE / January 11, 2023 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2023 Companies to Watch Event, Jan...

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical innovator, is enrolling patients in the United States and Europe for its potentially pivotal global clinical trial in humans for its lead drug candidate designed to treat glioblastoma multiforme (“GBM”), a common and one of th...

Cancer is a leading cause of death globally, with cancer types such as lung cancer, breast cancer and colorectal cancer being responsible for most cancer deaths. Over the last year, research in this particular field has made significant strides. Below, we look at some of the developments th...

CNS Pharmaceuticals to Present at the Virtual Investor 2023 Companies to Watch Event PR Newswire Live video webcast on Wednesday, January 18 th at 10:00 AM ET HOUSTON , January 5, 2023 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNS...

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced its appointment of Faith L. Charles as chair of its board of directors. Since 2010, Char...

CNS Pharmaceuticals is conducting a potentially pivotal clinical trial in the United States and Europe to establish the effectiveness of a drug candidate for combating incurable glioblastoma (“GBM”) brain cancers CNS’s flagship drug candidate is called Berubicin, a product ...